托法替尼
医学
斑秃
白癜风
皮肤病科
泛秃
相伴的
耐火材料(行星科学)
不利影响
银屑病
特应性皮炎
内科学
天体生物学
物理
类风湿性关节炎
作者
Patrick O Perche,Caitlin G Purvis,Rita O Pichardo
出处
期刊:Journal of Drugs in Dermatology
[SanovaWorks]
日期:2022-11-01
卷期号:21 (12): 1366-1368
被引量:2
摘要
In the last several years, oral tofacitinib has become an increasingly utilized off-label treatment option for immune-mediated skin conditions such as alopecia areata (AA), vitiligo, plaque psoriasis, and atopic dermatitis. Few case reports exist of patients with concomitant AA and vitiligo treated with tofacitinib.Photographs of the patient's affected disease areas were obtained at initiation of tofacitinib 5 mg twice daily (BID) and subsequent return visits over two years of treatment. A PubMed search for case reports and other relevant literature was performed using the keywords: alopecia areata, vitiligo, and tofacitinib.Two case reports in the literature describe patients with concomitant AA and vitiligo who were treated with tofacitinib. Both cases use adjuvant therapy or continued therapy, in addition to oral tofacitinib. Our patient was treated with low-dose tofacitinib monotherapy and had marked improvement in her AA and vitiligo, with moderate re-pigmentation of her hands and regrowth of the scalp and eyebrows within several months of treatment. Treatment effects continued to improve over two years without noted adverse effects.Tofacitinib 5 mg BID monotherapy was an efficacious and well-tolerated treatment option for a patient with refractory alopecia areata and vitiligo. J Drugs Dermatol. 2022;21(12):1366-1368. doi:10.36849/JDD.6826.
科研通智能强力驱动
Strongly Powered by AbleSci AI